Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds

Sponsor
The Metis Foundation (Other)
Overall Status
Completed
CT.gov ID
NCT04079998
Collaborator
Indiana University (Other)
38
1
2
21.2
1.8

Study Details

Study Description

Brief Summary

The objective of the study is to evaluate Procellera® , a novel FDA approved antimicrobial wound dressing in a prospective, randomized, controlled clinical study. The hypothesis is that when the dressing is moistened, the low electric field created by moisture-activated elemental silver and zinc electro-couple will prevent formation of biofilm in wounds or to disrupt existing biofilm.

Condition or Disease Intervention/Treatment Phase
  • Device: Procellera®
  • Other: Standard of Care
N/A

Detailed Description

The healing of traumatic wounds, to include burns, can be compromised by the presence of infection so efforts are made to prevent or diagnose infection early in order to mitigate the negative impact on healing. Electric stimulation has previously been shown to have both bacteriostatic and bactericidal effects in wounds. Until now, administering low intensity electric field/micro-current as a therapy to mitigate biofilm infection and to improve wound healing was not feasible. In this study the investigators will use Procellera® , a FDA approved fabric based wireless electroceutical dressing (WED) consisting of a silver-zinc electro-couple for the prevention of wound biofilm formation. The dressing generates a low electric field (~1V) upon activation by a moist environment, which mitigates biofilm formation and promotes wound healing. The objectives of the study are to evaluate the efficacy of a wireless electroceutical dressing to prevent the formation or disrupting existing biofilms. The investigators will conduct a prospective, randomized controlled clinical trial using the Procellera® dressing compared to the standard of care. Treatment sites will be randomized to either receiving Procellera® or the standard of care treatment. Objective measurements and assessments will be completed during subject follow-up visits for up to one month post treatment. This includes biopsies to calculate bacterial load by assessing colony forming unit (CFU) count and bacterial film visualization using scanning electron microscopy, histology, clinical assessment of infection, Transepidermal Water Loss (TEWL) and wound photography.

Study Design

Study Type:
Interventional
Actual Enrollment :
38 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will have two wound sites that will be randomized to receive either the standard of care treatment or the Procellera® (electroceutical) dressing.Participants will have two wound sites that will be randomized to receive either the standard of care treatment or the Procellera® (electroceutical) dressing.
Masking:
Single (Outcomes Assessor)
Masking Description:
Biopsies obtained will be sent to Indiana University for blinded processing and analysis.
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Controlled Study to Determine the Superiority of a Fabric-based Wireless Electroceutical Dressing, Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds
Actual Study Start Date :
Feb 28, 2019
Actual Primary Completion Date :
Nov 13, 2020
Actual Study Completion Date :
Dec 3, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Procellera® dressing

The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.

Device: Procellera®
Application of Procellera® dressing.

Active Comparator: Standard of Care

The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.

Other: Standard of Care
Application of standard of care dressings as prescribed.

Outcome Measures

Primary Outcome Measures

  1. Presence of biofilm [Day seven]

    Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy.

  2. Rate of eradication of biofilm production [Day 7]

    Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy.

Secondary Outcome Measures

  1. Incidence of infection [Day 0-30]

    Wounds will be assessed for the presence of clinical evidence indicating infection.

  2. Percent epithelialization [Day 7]

    The percentage of epitheliazation will be assessed utilizing clinical assessments and the Silhouette Star wound camera.

  3. Quality of healing [Day 30]

    Quality of healing post-epithelialization as measured by the validated Patient Observer Scar Assessment Scale (POSAS)

  4. Quantitative bacterial load calculation [Day 7]

    Quantitative bacterial load will be assessed by obtaining a wound biopsy and analyzed by performing colony forming unit counts

  5. Incidence of adverse events [Day 0-30]

    The incidence of adverse events will be reported to assess safety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18-65 years of age

  • Willing and able to provide informed consent

  • Participant has acute partial-thickness or full-thickness wounds caused by trauma or partial-thickness burns that are ≥ 300 cm2 in size in one contiguous area or two separate wound sites ≥ 150 cm2 each

Exclusion Criteria:
  • Pregnancy

  • Prisoner

  • Active malignancy or immunosuppressive therapy

  • Current systemic steroid use

  • Known allergy or sensitivity to silver or zinc

  • Participant's proposed study wound site has any of the following conditions:

  • Location is on the hands, face or feet

  • Full-thickness burn wounds

  • Exposure of visceral organs

  • Exposure of hardware or prosthetic exposure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brooke Army Medical Center Fort Sam Houston Texas United States 78234

Sponsors and Collaborators

  • The Metis Foundation
  • Indiana University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Metis Foundation
ClinicalTrials.gov Identifier:
NCT04079998
Other Study ID Numbers:
  • C.2018.065
First Posted:
Sep 6, 2019
Last Update Posted:
Jan 22, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 22, 2021